2026-10-19T01:10:07Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/139562026-10-18T21:14:19Zopenairedrivercom_ebyu_10000col_ebyu_10001

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experienceAygen, BilgehanDemirtürk, NeşeYıldız, OrhanÇelen, Mustafa KemalÇelik, İlhamiBarut, ŞenerUral, OnurBatırel, AyşeMıstık, ReşitŞimşek, FundaAsan, AliErsöz, GüldenTürker, NesrinBilgin, HüseyinKınıklı, SamiKarakeçili, FarukZararsız, GökmenGünal, ÖzgürAkhan, SılaTülek, Neclaİnan, DilaraÇağatay, AtahanGürbüz, YunusŞener, AlperÇelikbaş, Aysel KocagülÇetinkaya, Rıza AytaçKadanalı, AytenHakyemez, İsmail NecatiKuruüzüm, ZiyaÖzel, Selcan ArslanKorkmaz, PınarTuna, NazanSaltoğlu, NeşeTarakçı, HüseyinUysal, BurcuKaragöz, ErgenekonKoçulu, SafiyeAyaz, CelalGüzel, Deniz KamalakTürkoğlu, EmineDemir, Nazlım AktuğŞimşek, SümeyraKantürk, ArzuAkça, Mustafa ÖzgürEvik, GülizÖrmen, BaharSili, UluhanHatipoğlu, Çiğdem AtamanBinay, Umut DevrimKılıç, SırrıArslan, KaderYenilmez, ErcanÇomoğlu, ŞenolKoç, Meliha MeriçGökgöz, AltanDursun, Zehra BeştepeSümer, ŞuaHeper, YaseminYıldırmak, TanerÖztürk, SinanChronic hepatitis CDasabuvirHCV genotypes 1 and 4OmbitasvirParitaprevirReal-world effectiveness2-NaphthylamineAdultAgedAged, 80 and overAnilidesAntiviral AgentsCyclopropanesDatabases, FactualDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis C, ChronicHumansLactams, MacrocyclicMaleMiddle AgedProlineRibavirinRitonavirSulfonamidesSustained Virologic ResponseTurkeyUracilBackground/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r ± DSV ± RBV combination regimen in a real-world clinical practice. Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r ± DSV ± RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed. Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naïve. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%. Conclusion: The present real-life data of Turkey for the OBV/PTV/r ± DSV ± RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. © Copyright 2020 by The Turkish Society of Gastroenterology • Available online at turkjgastroenterol.orgAVES2020Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/13956https://doi.org/10.5152/tjg.2020.191971300-4948enTurkish Journal of Gastroenterologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/13956